Company / EPS (Diluted)
RECURSION PHARMACEUTICALS, INC. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.58
FY2025
5-year range
-$3.99 / -$1.36
FY2021-FY2025
Trend
-16.2%
vs FY2024
Sector context
#106 of 204
Health Care
What the data says
At $-1.58, RECURSION PHARMACEUTICALS, INC.'s eps (diluted) ranks #106 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 7 years, ranging from $-3.99 in FY2022 to $-1.36 in FY2024.
Based on SEC 10-K filings.
-1.58 in FY2025.
Declined from $-1.49 to $-1.58 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#106 of 204 in Health CareTop 52% of 204This company -$1.58 Sector average -$0.98
▼
-61.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 16.2% year-over-year.
- Ranks #106 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.58 | -16.2% |
| FY2024 | -$1.36 | +8.7% |
| FY2023 | -$1.49 | +62.7% |
| FY2022 | -$3.99 | -39.0% |
| FY2021 | -$2.87 | +28.1% |
| FY2020 | -$3.99 | -39.0% |
| FY2019 | -$2.87 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026